Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort-Reference-Cited by-同舟云学术

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

Published:2015-09 Issue:7 Volume:113 Page:989-995
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Portal Alix,Pernot Simon,Tougeron David,Arbaud Claire,Bidault Anne Thirot,de la Fouchardière Christelle,Hammel Pascal,Lecomte Thierry,Dréanic Johann,Coriat Romain,Bachet Jean-Baptiste,Dubreuil Olivier,Marthey Lysiane,Dahan Laetitia,Tchoundjeu Belinda,Locher Christophe,Lepère Céline,Bonnetain Franck,Taieb Julien

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015328.pdf

Reference26 articles.

1. Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S (2011) 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 80: 301–306.

2. Bachet J-B, Mitry E, Lièvre A, Lepère C, Vaillant J-N, Declety G, Parlier H, Emile J-F, Julié C, Rougier P (2009) Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. Gastroenterol Clin Biol 33: 1036–1044.

3. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L (2014) Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer 50: 2983–2993.

4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul J-L, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet J-B, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–1825.

5. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul J-L, Cattan S, Phelip J-M, Hammel P, Chauffert B, Michel P, Legoux J-L, Rougier P, Bedenne L, Seitz J-F Fédération Francophone de Cancérologie Digestive (2010) Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 59: 1527–1534.

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Gemcitabine Plus Nab-paclitaxel in Second-line Treatment of Metastatic Pancreatic Cancer: a Multicenter Retrospective Study in Turkey;2024-09-10

2. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study;Cancer Biology & Medicine;2024-07-26

3. Head‐to‐head comparison of treatment sequences in advanced pancreatic cancer—Real‐world data from the prospective German TPK clinical cohort study;International Journal of Cancer;2024-07-02

4. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment;Cancer Medicine;2024-06

5. Hong Kong consensus recommendations on the management of pancreatic ductal adenocarcinoma;Hong Kong Medical Journal;2024-04-09